UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Dublin, April 07, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.
Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.
Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.
The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2015 to 2025. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.
Profiles of 162 companies involved in developing RNAi technologies are presented along with 234 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs. The bibliography contains selected 640 publications that are cited in the report. The text is supplemented with 38 tables and 14 figures.
Key Topics Covered:
Executive Summary
1. Technologies for suppressing gene function
2. RNAi Technologies
3. MicroRNA
4. Methods of delivery in RNAi
5. RNAi in Research
6. RNAi in drug discovery
7. Therapeutic applications of RNAi
8. Safety, regulatory and patent issues
9. Markets for RNAi Technologies
10. Companies involved in RNAi Technologies
11. References
For more information visit http://www.researchandmarkets.com/research/rtpd7m/rnai
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Genomics
